Skip to content

Q2 FY25 Earnings Results

Q2 FY25 earnings, Jul–Sep 2024: 5,887 Indian listed companies have reported; median profit growth is +6.2% on last year. Quarter ended 30 Sep 2024.

Clear filters 201–263 of 263
CompanyRevenue (₹ Cr)Profit (₹ Cr)Per share8Q profit
Symbol Sector Reported YoY QoQ Reported YoY EPS vs consensus Trend
CONCORDDRUGSLTD Healthcare12up+60.4%up+86.5%0down−90.6%0.05No estimate
JEEVANSCIENTIFICTECHNOLOGYLTD Healthcare11up+41.4%down−11.5%0n/a0.16No estimate
SOURCENATURALFOODSLTD Source Natural Foods & Herbal Supplements LtdHealthcare10up+48.9%up+25.7%1up+342.1%1.30No estimate
Solvay Pharma India Ltd(merged) Healthcare10down−36.5%down−34.4%−1down−135.6%−0.95No estimate
VASUNDHARARASAYANSLTD Healthcare10up+4.9%up+28.2%1up+5.8%4.63No estimate
ZENOTECHLABORATORIESLTD Healthcare10down−15.3%down−1.4%1down−52.3%0.22No estimate
PARMAXPHARMALTD Healthcare9up+128.0%up+18.7%0n/a−0.59No estimate
APRAMEYA Aprameya Engineering LtdHealthcare9n/an/a−2n/a−0.91No estimate
GUJINJECLTD Gujarat Inject (Kerala) LtdHealthcare9n/aup+182.3%1up+6,000.0%0.04No estimate
GKB GKB Ophthalmics LtdHealthcare8up+13.6%down−4.2%−2n/a−4.07No estimate
Perk Pharmaceuticals Ltd Healthcare8n/aup+10.9%0n/a0.33No estimate
Anus Laboratories Ltd Healthcare8down−55.6%down−95.7%−14n/a−0.66No estimate
KMSMEDISURGILTD Healthcare8up+9.2%n/a0down−86.7%0.24No estimate
SHUKRAPHAR Shukra Pharmaceuticals LtdHealthcare6down−76.0%up+100.0%1down−80.0%0.01No estimate
NECLIFE Nectar Lifescience LtdHealthcare6down−98.5%down−98.3%6up+500.0%0.25No estimate
A D S Diagnostic Ltd Healthcare6down−22.8%up+41.9%0down−55.7%2.14No estimate
PHAARMASIALTD Healthcare6down−31.4%down−28.5%−1n/a−0.94No estimate
DECIPHERLABSLTD Healthcare6down−21.6%down−21.1%−1n/a−1.32No estimate
BERYLDRUGSLTD Healthcare6down−30.3%down−10.3%0down−96.3%0.02No estimate
PHARMAIDSPHARMACEUTICALSLTD Healthcare5n/aup+10.8%−2n/a−0.55No estimate
VEERHEALTHCARELTD Healthcare5up+34.5%up+150.0%0down−23.1%0.15No estimate
VILINBIO Vilin Bio Med LtdHealthcare4down−41.3%n/a0down−84.4%0.09No estimate
FABINOLTD Fabino Enterprises LtdHealthcare4down−67.0%n/a0down−66.7%0.14No estimate
SHREEPACETRONIXLTD Healthcare4down−22.8%down−16.7%0down−95.5%0.08No estimate
UNJHAFORMULATIONSLTD Healthcare4down−20.6%down−4.3%0n/a−0.25No estimate
GENESISIBRCINDIALTD CCME Global LtdHealthcare4n/an/a4n/a2.81No estimate
Sangam Health Care Products Ltd Healthcare4up+18.7%up+6.8%0down−65.0%0.05No estimate
BRAWNPHARMACEUTICALSLTD Brawn Biotech LtdHealthcare3up+13.0%down−18.7%0n/a−1.13No estimate
ISHITADRUGSINDUSLTD Ishita Drugs & Industries LtdHealthcare3down−25.7%up+7.9%0down−9.5%0.64No estimate
AUROLABORATORIESLTD Healthcare3down−76.9%down−45.8%0down−81.7%0.58No estimate
ZENITHHEALTHCARELTD Healthcare3down−13.2%up+17.9%0down−25.0%0.02No estimate
VIVANZABIOSCIENCESLTD Healthcare3down−60.6%up+23.0%0down−92.3%0.00No estimate
SUVEN Suven Life Sciences LtdHealthcare30.0%up+200.0%−50n/a−2.28No estimate
Span Divergent Ltd Healthcare3down−11.9%down−24.5%0n/a0.24No estimate
MEDINOVADIAGNOSTICSERVICELTD Medinova Diagnostic Services LtdHealthcare3down−10.8%up+2.8%1down−24.2%0.50No estimate
Medinova Diagnostic Services Ltd Healthcare3down−10.8%up+2.8%1down−24.2%0.50No estimate
VISTAPHARMACEUTICALSLTD Healthcare2down−28.2%up+38.3%−1n/a−0.26No estimate
BIOFILCHEM Biofil Chemicals & Pharmaceuticals LtdHealthcare2down−86.1%down−71.4%0down−83.3%0.01No estimate
SHREEGANESHBIOTECHINDIALTD Healthcare2down−51.9%down−44.4%0up+300.0%0.01No estimate
COLINZLABORATORIESLTD Healthcare2up+3.9%up+6.3%0up+33.3%0.64No estimate
GANGAPHARMACEUTICALSLTD Healthcare1down−0.8%n/a00.0%0.04No estimate
DESHRAKSHAKAUSHDHALAYALTD Healthcare1up+41.7%up+10.2%0up+66.7%0.34No estimate
VANTABIOSCIENCELTD Healthcare1down−83.3%n/a−2n/a−3.28No estimate
MEDICAPQ Medi Caps LtdHealthcare1down−54.0%up+237.9%0down−76.7%0.36No estimate
GENOMICVALLEYBIOTECHLTD Healthcare0up+200.0%up+31.3%0up+650.0%0.49No estimate
VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals LtdHealthcare0n/aup+70.0%0n/a−0.57No estimate
SHYAMAINFOLTD Shyama Computronics and Services LtdHealthcare0up+20.0%0.0%0up+100.0%0.02No estimate
RUBRAMEDICAMENTSLTD Centuple Global LtdHealthcare0down−82.8%down−50.0%0down−115.4%−0.07No estimate
ORTINGLOBE Ortin Global LtdHealthcare0down−81.5%down−76.2%0n/a−0.58No estimate
AMBALALSA Ambalal Sarabhai Enterprises LtdHealthcare0down−100.0%down−100.0%4up+669.6%0.56No estimate
TRANSCHEMLTD Healthcare0n/an/a1up+48.5%1.18No estimate
CHEMOPHARMALABORATORIESLTD Starsource Multitrade LtdHealthcare0n/an/a1up+38.6%4.07No estimate
TRIOCHEMPRODUCTSLTD Healthcare0n/an/a0n/a−1.63No estimate
KABRADRUGSLTD Healthcare0n/an/a0n/a−0.40No estimate
BACILPHARMALTD Healthcare0n/an/a0n/a0.81No estimate
KAMRONLABORATORIESLTD Adline Chem Lab LtdHealthcare0n/an/a0n/a−0.15No estimate
REKVINALABORATORIESLTD Rekvina Labs LtdHealthcare0n/an/a0n/a−0.06No estimate
RAYMEDLABSLTD Cresanto Global LimitedHealthcare0n/an/a0n/a−0.05No estimate
MPS Pharmaa Ltd Healthcare0n/an/a0n/a−0.12No estimate
TRANSPACTENTERPRISESLTD Healthcare0n/an/a0n/a−1.29No estimate
TAKE Take LtdHealthcare0down−100.0%n/a−2n/a−0.11No estimate
Transchem Ltd Healthcare0n/an/a1up+48.5%1.18No estimate
Harleystreet Pharmaceuticals Ltd(merged) Healthcare—n/an/a155up+22.0%4.96No estimate

About Q2 FY25 earnings data

When are Q2 FY25 results announced?
Q2 FY25 covers the Jul–Sep 2024 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
Why do some Q2 FY25 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No analyst consensus was available for Q2 FY25, so no beat/miss verdict is shown. Revenue and profit growth are taken from reported results and cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q2 FY25?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.

Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.